caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1609883883

Michael RabinMD

Hematology-OncologyBoston, MAI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Michael Rabin's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 13 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
Nikhil Ramaiya
Diagnostic Radiology · West Palm Beach, FL
39140
Francine Jacobson
Diagnostic Radiology · Roanoke, VA
38171
Rachna Madan
Diagnostic Radiology · Boston, MA
34163
Jyothipriya Jagannathan
Diagnostic Radiology · Jamaica Plain, MA
31118
Ritu Gill
Diagnostic Radiology · New York, NY
2066
CAPE COD HOSPITAL INC19126
Lucian Chirieac
Pathology · Boston, MA
1649
Scott Swanson
General Surgery · Boston, MA
1380
Quest Diagnostics Massachusetts Llc
Clinical Laboratory · Marlborough, MA
1369
Lynette Sholl
Pathology · Boston, MA
1323
KIM, CHUN1232
Raymond Mak
Radiation Oncology · Boston, MA
1275
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
390
Unique beneficiaries
—
Total services
685
Distinct HCPCS
8
Medicare payment
$57K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 360 Hematology-Oncology providers in MA — above median (cohort median 624).
PRESCRIBING · PART D · 2024
Total Rx claims
153
Beneficiaries
—
Total drug cost
$1.8M
Distinct drugs
3
Brand share
69.9%
Top prescribed drugs
Osimertinib Mesylate107 claims
Dexamethasone25 claims
Levothyroxine Sodium21 claims
QUALITY · MIPS · 2024
Final MIPS score
84.1
Quality
65.0
Cost
69.1
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.38%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.